Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR). 1 ...

One of its most peculiar characteristics is a strong association with upper urothelial cancer (UUC). BEN-related UUC has the same histological features as other forms of UUC in general ...

Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis. Bacillus ...

(OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of ...

The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...

GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Nataliya Mar discussing real world toxicity profile of enfortumab vedotin with or without pembrolizumab in ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.